Pfizer Pharma GmbH
- Legal form
- GmbH
- Seat
- Berlin, Germany
Based on the notices and sources Inteliwert covers; not a complete record. Last checked 19 October 2026.
Identifiers
Not found in the indexed notices.
Track record in public tenders
Awards in the covered notices over the last 36 months, per CPV division.
| CPV division | Awards | Award value (excl. VAT) | Buyers | Repeat buyers | First award | Last award |
|---|---|---|---|---|---|---|
| 33 Medical equipments, pharmaceuticals and personal care products | 5 | — | 1 | 1 | 19 October 2026 | 19 October 2026 |
Awards
- Vergaben von Arzneimitteln und apothekenüblichen Produkten zum 01.01.2027 und 01.07.2027Buyer: PBMG eG · Awarded: 19 October 2026 · CPV 33600000
- Vergaben von Arzneimitteln und apothekenüblichen Produkten zum 01.01.2027 und 01.07.2027Buyer: PBMG eG · Awarded: 19 October 2026 · CPV 33600000
- Vergaben von Arzneimitteln und apothekenüblichen Produkten zum 01.01.2027 und 01.07.2027Buyer: PBMG eG · Awarded: 19 October 2026 · CPV 33600000
- Vergaben von Arzneimitteln und apothekenüblichen Produkten zum 01.01.2027 und 01.07.2027Buyer: PBMG eG · Awarded: 19 October 2026 · CPV 33600000
- Vergaben von Arzneimitteln und apothekenüblichen Produkten zum 01.01.2027 und 01.07.2027Buyer: PBMG eG · Awarded: 19 October 2026 · CPV 33600000
Certifications and prequalification
No certification or prequalification found in the covered sources.
A certification missing here is unknown, not absent.
Website and LinkedIn
Not found in the indexed notices.
Open tenders that might fit
Possible match based on public information
Companies Inteliwert knows from its sources, not the whole market. Inteliwert does not judge eligibility, fit or chances.
-
OpenTenderEstablished supplier
Arzneimittel- Rahmenrabattverträge nach §130a Absatz 8 SGB V
Reasons
- Won a contract in CPV group 336 (2026-10-19) Evidence · checked 4 Nov 2026
- 5 awards in this field in 36 months, from 1 buyer Evidence · checked 4 Nov 2026
Last checked 26 Oct 2026, 15:14 (UTC+01:00)Official notice -
OpenTenderEstablished supplier
1/DLII6/VM155 - RV Arzneimittel, divers
Reasons
- Won a contract in CPV group 336 (2026-10-19) Evidence · checked 4 Nov 2026
- 5 awards in this field in 36 months, from 1 buyer Evidence · checked 4 Nov 2026
Last checked 4 Nov 2026, 16:10 (UTC+01:00)Official notice -
OpenTenderEstablished supplier
Generikaausschreibung
Reasons
- Won a contract in CPV group 336 (2026-10-19) Evidence · checked 5 Nov 2026
- 5 awards in this field in 36 months, from 1 buyer Evidence · checked 5 Nov 2026
Last checked 4 Nov 2026, 16:10 (UTC+01:00)Official notice -
OpenTenderEstablished supplier
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Certolizumab pegol (ATC-Code nach WHO: L04AB05)
Reasons
- Won a contract in CPV group 336 (2026-10-19) Evidence · checked 4 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 4 Nov 2026
- 5 awards in this field in 36 months, from 1 buyer Evidence · checked 4 Nov 2026
Last checked 26 Oct 2026, 15:21 (UTC+01:00)Official notice -
OpenTenderEstablished supplier
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Certolizumab pegol (ATC-Code nach WHO: L04AB05)
Reasons
- Won a contract in CPV group 336 (2026-10-19) Evidence · checked 4 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 4 Nov 2026
- 5 awards in this field in 36 months, from 1 buyer Evidence · checked 4 Nov 2026
Last checked 26 Oct 2026, 15:21 (UTC+01:00)Official notice -
OpenTenderEstablished supplier
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Infliximab zur subkutanen Injektion (ATC-Code nach WHO: L04AB02)
Reasons
- Won a contract in CPV group 336 (2026-10-19) Evidence · checked 5 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 5 Nov 2026
- 5 awards in this field in 36 months, from 1 buyer Evidence · checked 5 Nov 2026
Last checked 4 Nov 2026, 16:10 (UTC+01:00)Official notice -
OpenTenderEstablished supplier
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Tocilizumab (ATC-Code nach WHO: L04AC07)
Reasons
- Won a contract in CPV group 336 (2026-10-19) Evidence · checked 5 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 5 Nov 2026
- 5 awards in this field in 36 months, from 1 buyer Evidence · checked 5 Nov 2026
Last checked 4 Nov 2026, 16:10 (UTC+01:00)Official notice -
OpenTenderEstablished supplier
Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Reasons
- Won a contract in CPV group 336 (2026-10-19) Evidence · checked 4 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 4 Nov 2026
- 5 awards in this field in 36 months, from 1 buyer Evidence · checked 4 Nov 2026
Last checked 4 Nov 2026, 12:10 (UTC+01:00)Official notice -
OpenTenderEstablished supplier
Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Reasons
- Won a contract in CPV group 336 (2026-10-19) Evidence · checked 4 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 4 Nov 2026
- 5 awards in this field in 36 months, from 1 buyer Evidence · checked 4 Nov 2026
Last checked 4 Nov 2026, 14:10 (UTC+01:00)Official notice -
OpenTenderEstablished supplier
Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Reasons
- Won a contract in CPV group 336 (2026-10-19) Evidence · checked 4 Nov 2026
- Seat in the same country as the place of performance Evidence · checked 4 Nov 2026
- 5 awards in this field in 36 months, from 1 buyer Evidence · checked 4 Nov 2026
Last checked 4 Nov 2026, 14:10 (UTC+01:00)Official notice
Is this your company?
Send corrections, or ask us to remove the profile, to hello@inteliwert.com. You can also ask that the company never be tagged on LinkedIn.
About this profile
Each fact on this page shows its source: a public notice, an open-data register (GLEIF, Wikidata) or the company’s own website. Inteliwert does not rate companies and does not judge eligibility, fit or chances.
Based on the notices and sources Inteliwert covers; not a complete record.
Last checked 19 October 2026.